Humanin vs MOTS-c
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Humanin or MOTS-c?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Humanin and MOTS-c?
Humanin inhibits BAX-mediated apoptosis for neuroprotection (with cancer survival concern); MOTS-c activates AMPK for insulin sensitivity and metabolic regulation - neuroprotective vs. metabolic, from different mitochondrial gene regions.
Evidence Comparison
Humanin: Hashimoto 2001 discovery, multiple independent groups, strong mechanistic characterization via BAX inhibition. MOTS-c: Yang 2016 (Cell Metabolism), independently replicated AMPK-mediated metabolic effects. Both are animal-only for efficacy; both have good independent mechanistic validation.
Evidence Context Favoring Humanin
Neuroprotection, Alzheimer disease models, or apoptosis research - noting the BAX inhibition cancer concern.
Evidence Context Favoring MOTS-c
Metabolic aging, insulin sensitivity, or AMPK pathway research targeting energy metabolism.
Side-by-Side Snapshot
| Evidence grade | Humanin: Level D MOTS-c: Level D |
|---|---|
| Research status | Humanin: Preclinical MOTS-c: Preclinical |
| Primary category | Humanin: Anti-Aging & Longevity MOTS-c: Anti-Aging & Longevity |
| Cited studies | Humanin: 3 MOTS-c: 3 |